NBIX
Two years in, the data still looks sturdy
Neurocrine Biosciences just rolled out fresh two-year data for CRENESSITY, its treatment for adults with classic congenital adrenal hyperplasia, and the headline is pretty simple: the drug still seems to be doing the job without making patients choose between control and a more natural steroid regimen.
About 70% of treated patients landed in physiologic-range glucocorticoid dosing at two years. That matters because chronic steroid dosing can be a balancing act worthy of a tightrope walker — too much, and you pile on side effects; too little, and you lose disease control.
Why investors should care
The study also showed that 75% of patients who started out on dexamethasone were able to move off it altogether. That’s not just a medical footnote; it’s a signal that CRENESSITY may be helping patients shift to a more physiologic regimen without blowing up androgen control.
For a drug story, durability is everything. One-year data can get people in the door. Two-year data is where you ask, “Okay, but does it still work when real life has had time to do its thing?” Neurocrine is trying to answer that with a confident yes.
The bigger picture
The company says these results reinforce CRENESSITY’s long-term safety and efficacy, and they were presented at the American Association of Clinical Endocrinology’s 2026 annual meeting. For NBIX, the takeaway is that one of its newer growth assets is showing staying power — which is exactly the kind of thing investors like when they’re trying to separate durable franchises from flashy science projects.
Big picture: in biotech, “works and keeps working” is basically the gold standard. Neurocrine just got another lap around that track.